Texas Tech University

Commercialization Success

The Texas Tech University System increased inventions disclosed, patents filed, licenses executed and gross revenues generated in fiscal year 2014. The Office of Research Commercialization is proud to support a robust and growing innovation culture as represented by the following report showing consistent innovation increases year-to-year.

Pheromone composition to stimulate reproduction in female suids and methods of use

Patent No. 9,480,689
TTUS Inventor: Dr. John J. McGlone
Licensed to Animal Biotech

Abstract
The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.


System and method for evaluating wind flow fields using remote sensing devices

Patent No. 9,519,056
TTUS Inventors: Dr. John Schroeder, Dr. Brian Hirth, and Jerry Guynes
Licensed to Smartwind Technologies

Abstract
The present invention provides a system and method for obtaining data to determine one or more characteristics of a wind field using a first remote sensing device and a second remote sensing device. Coordinated data is collected from the first and second remote sensing devices and analyzed to determine the one or more characteristics of the wind field. The first remote sensing device is positioned to have a portion of the wind field within a first scanning sector of the first remote sensing device. The second remote sensing device is positioned to have the portion of the wind field disposed within a second scanning sector of the second remote sensing device.

 

Apparatus and method for using radar to evaluate wind flow fields for wind energy applications

Patent No. 9,575,177
TTUS Inventors: Dr. John Schroeder, Dr. Brian Hirth, and Jerry Guynes
Licensed to Smartwind Technologies

Abstract
The present invention provides an apparatus and method for obtaining data to determine one or more characteristics of a wind flow field using one or more radars. Data is collected from the one or more radars, and analyzed to determine the one or more characteristics of the wind flow field. The one or more radars are positioned to have a portion of the wind flow field within a scanning sector of the one or more radars.

 

Methods and devices to control fluid volumes, reagent and particle concentration in arrays of microfluidic drops

Patent No. 9,637,718
TTUS Inventors: Dr. Siva A. Vanapalli and Dr. Swastika S. Bithi
Licensed to NeoFluidics

Abstract
The present invention includes a microfluidic device comprising one or more parking loops 12, each parking loop 12 comprising a bypass channel 14 and a lower branch 16 capable of retaining one or more drops, wherein bypass channel 14 has a smaller hydrodynamic resistance than the lower branch 16.

 

Composition and method for diagnosis and immunotherapy of lung cancer

Patent No. 9,518,989
TTUS Inventor: Dr. Maurizio Chiriva-Internati
Available for Licensing

Abstract
The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

 

TCR mimic antibodies as vascular targeting tools

Patent No. 9,555,108
TTUS Inventors: Dr. John A. Weidanz and Dr. Ulrich Bickel
Available for Licensing

Abstract
The present invention includes a method of delivering a therapeutic agent into and across an endothelial cell (EC) in a subject in need thereof, comprising: attaching to a T Cell receptor mimic (TCR mimic) an active agent to form a therapeutic agent; and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent effectively crosses the EC microvascular barrier. Furthermore, the present invention relates to methods of treating diseases (particularly neuronal diseases) or conditions comprising identifying a subject in need of such a treatment and administering to said subject a composition comprising a TCR mimic conjugated to an active agent.

 

Methods of reducing ignition sensitivity of energetic materials, methods of forming energetic materials having reduced ignition sensitivity, and related energetic materials

Patent No. 9,481,614
TTUS Inventors: Dr. Michelle Pantoya
Available for license

Abstract
An energetic material comprising an elemental fuel, an oxidizer or other element, and a carbon nanofiller or carbon fiber rods, where the carbon nanofiller or carbon fiber rods are substantially homogeneously dispersed in the energetic material. Methods of tailoring the electrostatic discharge sensitivity of an energetic material are also disclosed. Energetic materials including the elemental fuel, the oxidizer or other element, and an additive are also disclosed, as are methods of reducing ignition sensitivity of the energetic material including the additive. The additive is combined with the elemental fuel and a metal oxide to form the energetic material. The energetic material is heated at a slow rate to render inert the energetic material to ignition while the energetic material remains ignitable when heated at a fast rate.

 

Galectin-3C combination therapy for human cancer

Patent No. 9,744,212
TTUS Inventors: Dr. Maurizio Chiriva-Internati and Dr. Everardo Cobos
Available for Licensing

Abstract
The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

 

We Want to Hear from You!

Questions about the patent process? Interested in partnerships? Looking for specific available technologies at TTU? Send us an email and a member of our staff will reply promptly.

To submit a disclosure, please visit the Disclose an Invention page.

Captcha Verification
 

Office of Research Commercialization